Table 1 Study cohort (n = 17,747)
No. of patients (%) | ||
|---|---|---|
Study cohort on TMA | Biochemical relapse among categories | |
(n = 17,747) | ||
Follow-up (mo) | ||
n | 14,464 (81.5%) | 3612 (25%) |
Mean | 56.3 | – |
Median | 48 | – |
Age (y) | ||
≤ 50 | 433 (2.4%) | 66 (15.2%) |
51–59 | 4341 (24.5%) | 839 (19.3%) |
60–69 | 9977 (56.4%) | 2073 (20.8%) |
≥ 70 | 2936 (16.6%) | 634 (21.6%) |
Pretreatment PSA (ng/ml) | ||
< 4 | 2225 (12.6%) | 313 (14.1%) |
4–10 | 10,520 (59.6%) | 1696 (16.1%) |
10–20 | 3662 (20.8%) | 1043 (28.5%) |
> 20 | 1231 (7%) | 545 (44.3%) |
pT stage (AJCC 2002) | ||
pT2 | 11,518 (65.2%) | 1212 (10.5%) |
pT3a | 3842 (21.7%) | 1121 (29.2%) |
pT3b | 2233 (12.6%) | 1213 (54.3%) |
pT4 | 85 (0.5%) | 63 (74.1%) |
Gleason grade | ||
≤ 3 + 3 | 3570 (20.3%) | 264 (7.4%) |
3 + 4 | 9336 (53%) | 1436 (15.4%) |
3 + 4 Tert.5 | 798 (4.5%) | 165 (20.7%) |
4 + 3 | 1733 (9.8%) | 683 (39.4%) |
4 + 3 Tert.5 | 1187 (6.7%) | 487 (41%) |
≥ 4 + 4 | 999 (5.7%) | 531 (53.2%) |
pN stage | ||
pN0 | 10,636 (89.4%) | 2243 (21.1%) |
pN+ | 1255 (10.6%) | 700 (55.8%) |
Surgical margin | ||
Negative | 14,297 (80.8%) | 2307 (16.1%) |
Positive | 3388 (19.2%) | 1304 (38.5%) |